吸烟史预测晚期非小细胞肺癌患者对PARP抑制剂维利帕尼的敏感性
这项2期试验的探索性分析显示,在未经治疗的晚期非小细胞肺癌患者中,近期吸烟者接受维利帕尼联合卡铂/紫杉醇较对照显著改善无进展生存和总生存(HR=0.38,p<0.01;HR=0.43,p<0.01),而既往吸烟者和从不吸烟者无显著获益,毒性可接受。
要点
- 在近期吸烟者中,维利帕尼联合化疗较对照显著改善无进展生存(HR=0.38,p<0.01)和总生存(HR=0.43,p<0.01)。
- 既往吸烟者和从不吸烟者未观察到维利帕尼的显著生存获益。
- 近期吸烟者接受维利帕尼治疗的3/4级不良事件发生率更高,但所有级别和严重不良事件在两组间相似。
核心结论
- 吸烟史可预测维利帕尼联合化疗的疗效,且无论吸烟史如何,毒性可接受。
- 计划对正在进行的维利帕尼治疗非小细胞肺癌的3期研究中的近期吸烟者进行预设分析。
研究设计与样本
- 2期试验的探索性分析,患者按2:1随机接受卡铂/紫杉醇联合维利帕尼120 mg(n=105)或安慰剂(n=53)。
- 患者按组织学亚型和吸烟史分层:近期吸烟者(n=95)、既往吸烟者(n=42)和从不吸烟者(n=21)。
- 血浆可替宁水平作为吸烟的化学指标,通过全外显子组测序评估突变状态(n=38)。
主要发现
- 近期吸烟者接受维利帕尼治疗较对照显著改善无进展生存(HR=0.38,p<0.01)和总生存(HR=0.43,p<0.01)。
- 从不吸烟者接受维利帕尼治疗的无进展生存HR=1.025(p=0.971),总生存HR=1.33(p=0.638)。
- 测序数据显示突变负荷与维利帕尼获益无关。
- 近期吸烟者接受维利帕尼治疗的3级或4级不良事件发生率更高,所有级别和严重不良事件在两个治疗组间相似。
关键数值与推荐
- 近期吸烟者接受维利帕尼治疗的无进展生存HR=0.38(p<0.01),总生存HR=0.43(p<0.01)。
- 从不吸烟者接受维利帕尼治疗的无进展生存HR=1.025(p=0.971),总生存HR=1.33(p=0.638)。
临床怎么用
- 吸烟史可能用于预测晚期非小细胞肺癌患者对维利帕尼联合化疗的疗效。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
INTRODUCTION: Tobacco-related NSCLC is associated with reduced survival and greater genomic instability. Veliparib, a potent poly(adenosine diphosphate-ribose) polymerase inhibitor, augments platinum-induced DNA damage. A phase 2 trial of untreated advanced NSCLC showed a trend for improved outcomes (hazard ratio [HR] = 0.80, 95% confidence interval: 0.54-1.18, p = 0.27 for overall survival and HR = 0.72, 95% CI: 0.45-1.15, p = 0.17 for progression-free survival) when veliparib was added to carboplatin/paclitaxel. Here we report an exploratory analysis by smoking history. METHODS: Patients were randomized 2:1 to receive carboplatin/paclitaxel with veliparib, 120 mg (n = 105), or placebo (n = 53). Patients were stratified by histologic subtype and smoking history (recent smokers [n = 95], former smokers [n = 42], and never-smokers [n = 21]). Plasma cotinine level was measured as a chemical index of smoking. Mutation status was assessed by whole exome sequencing (n = 38). RESULTS: Smoking history, histologic subtype, age, Eastern Cooperative Oncology Group performance status, sex, and geographic region predicted veliparib benefit in univariate analyses. In multivariate analysis, history of recent smoking was most predictive for veliparib benefit. Recent smokers treated with veliparib derived significantly greater progression-free survival and overall survival benefits (HR = 0.38 [p < 0.01] and HR = 0.43 [p < 0.01]) than former smokers (HR = 2.098 [p = 0 0208] and HR = 1.62 [p = 0.236]) and never-smokers (HR = 1.025 [p = 0.971] and HR = 1.33 [p = 0.638]). Sequencing data revealed that mutational burden was not associated with veliparib benefit. The rate of grade 3 or 4 adverse events was higher in recent smokers with veliparib treatment; all-grade and serious adverse events were similar in both treatment arms. CONCLUSIONS: Smoking history predicted for efficacy with a veliparib-chemotherapy combination; toxicity was acceptable regardless of smoking history. A prespecified analysis of recent smokers is planned for ongoing phase 3 studies of veliparib in NSCLC.
引用
- Reck M, Blais N, Juhasz E, et al. Smoking History Predicts Sensitivity to PARP Inhibitor Veliparib in Patients with Advanced Non-Small Cell Lung Cancer. J Thorac Oncol. 2017. PMID: 28461256. doi:10.1016/j.jtho.2017.04.010
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。